Specialists in modelling non-communicable diseases

Tackling population health challenges means asking big questions, such as:

What impact will the increasing burden of chronic kidney disease have on healthcare costs over the next 20 years?
How can you look 10 to 20 years ahead to understand the impact of a new drug on its users and your revenue stream?
How do you determine whether it is clinically and financially feasible to progress a drug from Phase II to Phase III clinical trials?
What would be the health and economic benefits of earlier screening for the diagnosis and treatment of conditions such as chronic kidney disease or liver disease?
How can you boost a nation’s health with targeted help at different life stages?

And how do you even know which are the right questions to ask?

That’s where we can help.

Helping you make the best decisions

Our simulation and analysis expertise turns tomorrow’s population health questions and challenges into today’s focussed, specific, actionable decisions.

We can help you understand and explore those questions and challenges far into the future. Our scenario modelling will show you how different kinds of health interventions, drug innovations and policy changes can impact them.

And that will help you choose the best way forward.

Why Us?

Deep expertise in modelling non-communicable diseases, combined with entrepreneurial vision.

Why Us?

How do we do it?

We’ve created a specific process to help you find, ask and answer the right questions.


What have we done?

We’ve answered many different kinds of questions for many different organisations in over 70 countries.

Track Record

Why choose us?

We have an experienced and multi-disciplinary team of software engineers, population health and policy research experts, and mathematicians.


HealthLumen Blog

World Kidney Day 2024: Kidney health for all

It is estimated that a staggering 1 in 10 people worldwide are living with kidney disease (1). Despite its high global prevalence and mortality, CKD has surprisingly often been overlooked on health agendas across the globe up until now. In particular, low and middle-income countries are disproportionately affected by CKD and kidney failure, with a […]


How rare is rare? Quantifying the hidden population living with rare genetic diseases using genetic databases

Rare Disease Day is fast approaching, with a programme of activity being lined up, through international initiatives and country-specific programmes, in the UK for example to highlight challenges, raise awareness and generate change for the 300 million people worldwide living with one or more of the roughly 8,000 known rare diseases, as well as their […]


Join us at upcoming conferences to discuss the latest findings in the epidemiology of rare diseases.

It’s a well-established truism that rare diseases, whilst rare at the individual disease level, are collectively quite common, with some 300 million people worldwide living with a rare disease. However, are rare diseases actually as rare at the individual disease level as current estimates suggest  – what could be the extent of the “hidden population”? […]


NEWS: Policy interventions could reduce chronic liver disease and liver cancer in Europe by up to 7% by 2030 

Europe has the largest burden of diagnosed liver disease globally with almost 30 million people in the European Union alone estimated to be living with a chronic liver condition. Liver cirrhosis accounts for 1.8% of all deaths reported in Europe (170,000 deaths annually) with a 100% increase in cirrhosis deaths observed across the Eastern European […]